| Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial 2025 · curcumin group · ER+ breast cancer patients scheduled to receive tamoxifen | 500 mg | 26 weeks | 22 |
| Curcumin extract for prevention of type 2 diabetes 2012 · curcumin-treated group · Adults aged 35 years or older with prediabetes | 500 mg | 39 weeks | — |
| Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial 2024 · curcuRouge (cR) group · Adults aged 20 years or older with asymptomatic or mild COVID-19 | 180 mg | 7 days | 71 |
| Efficacy of Curcumin on Cognitive Function Scores in Women with Premenstrual Syndrome and Dysmenorrhea: A Triple-Blind, Placebo-Controlled Clinical Trial 2023 · curcumin group · Women with premenstrual syndrome and dysmenorrhea; age not stated | 500 mg | 30 days | 62 |
| The effect of curcumin on postpartum depression and anxiety in primiparous women: a double-blind randomized placebo-controlled clinical trial 2025 · Curcumin group · Primiparous women aged 18 years or older, within 12 hours after delivery, without a history of depression or other mental disorder and with EPDS score 12 or less | 500 mg | 8 weeks | 48 |
| Efficacy of a curcumin extract (Curcugen™) on gastrointestinal symptoms and intestinal microbiota in adults with self-reported digestive complaints: a randomised, double-blind, placebo-controlled study 2021 · curcumin · Adults aged 18–65, male and female, with self-reported gastrointestinal complaints and no diagnosed gastrointestinal disease | 500 mg | 8 weeks | 39 |
| Effect of Curcumin on Severity of Functional Dyspepsia: a Triple Blinded Clinical Trial 2021 · intervention group · Patients with functional dyspepsia according to Rome III criteria | 500 mg | 30 days | 39 |
| Effect and Safety of Phytosomal Curcumin Supplementation on Migraine Patients: A Randomized, Double-Blind and Placebo-Controlled Trial 2025 · intervention group · Patients with migraine without aura | 250 mg | 8 weeks | 35 |
| Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial 2019 · Group A · Patients with oral submucous fibrosis; age and sex not stated | 600 mg | 26 weeks | 30 |
| Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: a randomized clinical trial 2019 · curcumin group · Female adolescents aged 13–18 years with overweight or obesity | 500 mg | 10 weeks | 30 |
| Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial 2020 · curcumin · Women aged 18–40 with polycystic ovary syndrome (PCOS) | 500 mg | 12 weeks | 30 |
| The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial 2024 · curcumin group · Adults aged 18–70 with moderate or severe multiple trauma admitted to the trauma ICU | 500 mg | 7 days | 27 |
| Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial 2024 · NEC · Postmenopausal women with stage I–IIIa ER- and/or PR-positive breast cancer and aromatase inhibitor-induced arthropathy | 200 mg | 90 days | 22 |
| Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study 2020 · Theracurmin® · Patients with active mild-to-moderate Crohn's disease; age range and sex not reported | 360 mg | 12 weeks | 20 |
| The effectiveness of curcumin as a safe agent on hearing threshold improvement in patients with chronic kidney disease: a double-blind, placebo-controlled trial 2024 · curcumin group · Adults aged 18–50 with chronic kidney disease and hearing impairment | 500 mg | 12 weeks | 20 |
| A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study 2017 · 250 mg curcumin product group · Patients with active rheumatoid arthritis; age and sex not reported | 500 mg | 90 days | 12 |
| The dose-response effects of hydrolyzed curcumin on recovery, inflammation, and oxidative stress following exercise-induced muscle damage in males 2025 · LOW (single dose group) · Recreationally active males aged 18–41 years undergoing an exercise-induced muscle-damage protocol | 750 mg | 7 days | 11 |
| Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study 2017 · low-dose curcumin extract · People with major depressive disorder; age and sex not reported | 500 mg | 12 weeks | — |
| The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients' self-reported well-being: A randomized double-blind controlled trial 2018 · Curcuminoids nanomicelles plus mesalamine · Adults aged 18 years or older with mild to moderate ulcerative colitis | 240 mg | 4 weeks | — |
| Eight Weeks of a High Dose of Curcumin Supplementation May Attenuate Performance Decrements Following Muscle-Damaging Exercise 2019 · low dose of curcumin (50 mg of curcuminoids = 250 mg CurcuWIN®) · Men and women aged 19–29 years who were low to moderately trained and without stated musculoskeletal, medical, or metabolic contraindications to exercise | 750 mg | 8 weeks | — |
| Further Evidence of Benefits to Mood and Working Memory from Lipidated Curcumin in Healthy Older People: A 12-Week, Double-Blind, Placebo-Controlled, Partial Replication Study 2020 · curcumin group · Healthy men and women aged 50–85 years | 400 mg | 12 weeks | — |
| Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial 2021 · CGM (CurQfen) group · Adults with knee osteoarthritis | 400 mg | 6 weeks | — |
| Curcumin Reduces Depression in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial 2024 · curcumin-treated group (intervention) · Adults aged 35 years or older with obesity and type 2 diabetes diagnosed within the past 12 months; both sexes | 500 mg | 1 year | — |
| The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial 2024 · curcumin-treated (intervention) group · Adults aged 35 years or older with obesity and type 2 diabetes diagnosed within the previous year; sex not specified | 500 mg | 1 year | — |
| The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: A double-blind randomized controlled clinical trial 2025 · curcumin-treatment group · Children aged 5–15 years with newly diagnosed acute lymphoblastic leukemia receiving vincristine | 6 mg/kg | 90 days | 71 |
| A clinical trial of curcumin effect in comparison to metronidazole on the treatment of bacterial vaginosis 2025 · intervention group (curcumin) · Women aged 18–49 with bacterial vaginosis; not pregnant or breastfeeding | 80 mg | 7 days | 50 |
| Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial 2006 · curcumin · Patients with quiescent ulcerative colitis; age and sex not specified | 2 g | 26 weeks | 45 |
| Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial 2018 · nanocurcumin · Adults with definite or probable amyotrophic lateral sclerosis (ALS) | 80 mg | 1 year | 27 |
| Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial 2025 · Meriva · Adults with biopsy-proven nonalcoholic steatohepatitis (NASH); ages and sex not specified | 2 g | 72 weeks | 26 |
| Nano-curcumin supplementation in patients with mild and moderate acute pancreatitis: A randomized, placebo-controlled trial 2023 · nano-curcumin · Patients with mild or moderate acute pancreatitis | 80 mg | 2 weeks | 21 |
| Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial 2019 · CUFOX (FOLFOX ± bevacizumab plus curcumin) · Adults with metastatic colorectal cancer awaiting first-line chemotherapy | 2 g | — | 18 |
| Safety and efficacy of curcumin versus diclofenac in knee osteoarthritis: a randomized open-label parallel-arm study 2019 · curcumin group · Adults aged 38–65 years with symptomatic knee osteoarthritis and moderate knee pain | 1.5 g | 4 weeks | 70 |
| Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study 2018 · CuraMed · Men and women aged 40–77 with degenerative hypertrophic knee osteoarthritis | 1.5 g | 12 weeks | 66 |
| An Investigation into the Effects of a Curcumin Extract (Curcugen(®)) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study 2021 · Curcumin extract · Adults aged 45–70, male and female, with diagnosed knee osteoarthritis and knee pain for at least 3 months | 1 g | 8 weeks | 51 |
| Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial 2012 · curcumin · Male Iranian veterans aged 37–59 years with chronic pruritus after sulphur mustard exposure | 1 g | 4 weeks | 46 |
| Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial 2014 · bioavailability-boosted curcuminoids preparation · people with solid tumors receiving standard chemotherapy; age and sex not specified | 180 mg | 8 weeks | 40 |
| Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial 2023 · curcumin group · Adults aged 18–80 hospitalized with COVID-19 | 160 mg | 2 weeks | 37 |
| Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial 2020 · curcumin group · Patients with liver cirrhosis aged 20–70 years | 1 g | 90 days | 35 |
| Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial 2020 · curcumin · Adults aged 20–70 years with liver cirrhosis; sex not specified | 1 g | 12 weeks | 35 |
| Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study 2021 · BEC · Adults with mild-to-moderately active ulcerative colitis receiving standard-dose mesalamine | 100 mg | 90 days | 34 |
| Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study 2024 · TS-P1 group · healthy Japanese adults; age and sex not specified | 150 mg | 12 weeks | 33 |
| Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study 2024 · CR-033P group · healthy Japanese adults; age and sex not specified | 150 mg | 12 weeks | 33 |
| An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial 2015 · curcumin · Obese individuals; age range and sex not specified | 1 g | 30 days | 30 |
| A comparative study to evaluate the efficacy of lycopene and curcumin in oral submucous fibrosis patients: A randomized clinical trial 2018 · Group B · Patients with clinically diagnosed oral submucous fibrosis; age and sex not reported | 900 mg | 90 days | 30 |
| Curcumin administration and the effects on psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease 2020 · curcumin group · Patients aged 45–85 years with type 2 diabetes mellitus and coronary heart disease | 1 g | 12 weeks | 30 |
| Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study 2021 · nanocurcumin group · Inpatients with stable chronic schizophrenia and predominant negative symptoms; age and sex not specified | 160 mg | 16 weeks | 28 |
| Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial 2014 · combination group · Patients with major depressive disorder without concurrent suicidal ideation or other psychotic disorders; age and sex not reported | 1 g | 6 weeks | 27 |
| The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial 2023 · nano-micellar curcumin · Men with benign prostatic hyperplasia (BPH) | 160 mg | 90 days | 26 |
| Effects of nanomicelle curcumin capsules on prevention and treatment of oral mucosits in patients under chemotherapy with or without head and neck radiotherapy: a randomized clinical trial 2021 · Study group · Adults with cancer receiving chemotherapy, with or without head and neck radiotherapy, who were assessed before treatment and had no unrelated oral lesions | 160 mg | 7 weeks | 25 |
| Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial 2018 · bioavailable form of curcumin (Theracurmin) · Adults aged 51–84 years without dementia | 180 mg | 548 days | 21 |
| Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial 2026 · intervention · Patients with mild to moderate ulcerative colitis | 160 mg | 30 days | 21 |
| Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking Combined Supplementation With Curcumin And Resveratrol 2019 · Group A (Resveratrol + Curcumin) · Adults with chronic kidney disease and iron overload undergoing hemodialysis; age and sex not restricted | 500 mg | 12 weeks | 20 |
| Role of oral bio-enhanced curcumin in dry eye disease 2025 · Group B: active drug supplement group · Adults aged 18 years or older with bilateral mild to moderate dry eye disease | 1 g | 90 days | 20 |
| Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial 2014 · curcuminoids · Patients with mild-to-moderate knee osteoarthritis; age and sex range not reported | 1.5 g | 6 weeks | 19 |
| Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study 2014 · Theracurmin · Adults over 40 years with radiographically confirmed primary medial knee osteoarthritis, Kellgren–Lawrence grade II or III | 180 mg | 8 weeks | 18 |
| Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial 2014 · curcumin group · Patients with major depressive disorder without concurrent suicidal ideation or other psychotic disorders; age and sex not reported | 1 g | 6 weeks | 16 |
| Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients 2013 · curcumin · Adults aged 18 or older with noninflammatory breast cancer or carcinoma in situ receiving radiotherapy without concurrent chemotherapy | 1.5 g | 7 weeks | 14 |
| A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study 2017 · 500 mg curcumin product group · Patients with active rheumatoid arthritis; age and sex not reported | 1 g | 90 days | 12 |
| The dose-response effects of hydrolyzed curcumin on recovery, inflammation, and oxidative stress following exercise-induced muscle damage in males 2025 · HIGH (double dose group) · Recreationally active males aged 18–41 years undergoing an exercise-induced muscle-damage protocol | 1.5 g | 7 days | 12 |
| Effects of oral curcumin ingested before or after eccentric exercise on markers of muscle damage and inflammation 2019 · Curcumin before exercise (Exp. 1) · Healthy men; age not reported | 180 mg | 7 days | 10 |
| Effects of oral curcumin ingested before or after eccentric exercise on markers of muscle damage and inflammation 2019 · Curcumin after exercise (Exp. 2) · Healthy men; age not reported | 180 mg | 7 days | 10 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster) 2021 · lower-dose curcumin · Men aged 47–65 with Gulf War Illness | 1 g | 30 days | 10 |
| Effects of Curcumin C3 Complex® on Physical Function in Moderately Functioning Older Adults with Low-Grade Inflammation - A Pilot Trial 2023 · Curcumin C3 Complex® group · Adults aged 66–94 years with low-grade systemic inflammation and moderate physical functioning | 1 g | 12 weeks | 9 |
| Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study 2014 · curcumin · People with major depressive disorder; age and sex not specified | 1 g | 8 weeks | — |
| Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change 2015 · curcumin · Adults with major depressive disorder; age and sex not reported | 1 g | 8 weeks | — |
| Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2015 · curcumin · male adults aged 31–59 years with major depressive disorder receiving antidepressant medication | 1 g | 6 weeks | — |
| Safety, Tolerance, and Enhanced Efficacy of a Bioavailable Formulation of Curcumin With Fenugreek Dietary Fiber on Occupational Stress: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2016 · Standard curcumin · Adults experiencing occupational stress-related anxiety and fatigue; age range and sex not stated | 1 g | 30 days | — |
| Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults 2016 · curcumin treatment group · Community-dwelling older adults | 1.5 g | 1 year | — |
| Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study 2017 · high-dose curcumin extract · People with major depressive disorder; age and sex not reported | 1 g | 12 weeks | — |
| Effective Timing of Curcumin Ingestion to Attenuate Eccentric Exercise-Induced Muscle Soreness in Men 2019 · PRE · healthy young men | 180 mg | 7 days | — |
| Effective Timing of Curcumin Ingestion to Attenuate Eccentric Exercise-Induced Muscle Soreness in Men 2019 · POST · healthy young men | 180 mg | 4 days | — |
| The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis 2020 · curcumin · Patients with mild-to-moderate ulcerative colitis | 1.5 g | 8 weeks | — |
| Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial 2020 · curcumin · Sedentary overweight/obese adults aged 50–80 years | 160 mg | 16 weeks | — |
| The effects of oral administration of curcumin-galactomannan complex on brain waves are consistent with brain penetration: a randomized, double-blinded, placebo-controlled pilot study 2022 · CGM · Healthy adults aged 35–65 years | 1 g | 30 days | — |
| The effects of oral administration of curcumin-galactomannan complex on brain waves are consistent with brain penetration: a randomized, double-blinded, placebo-controlled pilot study 2022 · Unformulated curcumin (UC) · Healthy adults aged 35–65 years | 1 g | 30 days | — |
| A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients 2021 · nano-curcumin group · COVID-19 patients; age and sex not reported | 160 mg | 2 weeks | — |
| Efficacy of Curcuminoids in Managing Postoperative Pain after Total Laparoscopic Hysterectomy: A Randomized Controlled, Open-Label Trial 2022 · experimental group · Women who underwent laparoscopic hysterectomy | 1 g | 3 days | — |
| Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial 2023 · nano-curcumin group · Patients hospitalized with moderate-severe COVID-19; age and sex not specified | 140 mg | 2 weeks | — |
| Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial 2023 · curcumin plus omeprazole (C+O) · People with functional dyspepsia; age and sex distribution for this arm not reported | 1 g | 4 weeks | — |
| Curcumin plus piperine improve body composition in patients with inflammatory bowel disease: a randomized, double-blind, placebo-controlled clinical trial 2025 · curcumin · Adults aged 18 years or older with mild to moderate inflammatory bowel disease | 1 g | 12 weeks | — |
| Curcumin Supplementation Improves Gastrointestinal Symptoms in Women with Severe Obesity: A Double-Blind, Randomized, Placebo-Controlled Trial-A Pilot Study 2025 · curcuminoid group (CG) · Women aged 20–59 years with severe obesity (BMI ≥40 kg/m²), preparing for bariatric surgery | 1.5 g | 13 weeks | — |
| Bread enriched with phytosterols with or without curcumin modulates lipoprotein profiles in hypercholesterolaemic individuals. A randomised controlled trial 2019 · CC · People with hypercholesterolaemia; age and sex not reported | 228 mg | 4 weeks | — |
| Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial 2017 · IQP-CL-101 · Men and women aged 18–70 with irritable bowel syndrome meeting Rome III criteria and moderate-to-severe abdominal pain or discomfort | 660 mg | 8 weeks | 43 |
| Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study 2025 · chemotherapy with oral curcumin · Women with locally advanced or metastatic breast cancer | 1 g | 24 weeks | — |
| A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia 2016 · curcumin · People with oral leukoplakia | 3.6 g | 26 weeks | 111 |
| Add-on effect of curcumin to dienogest in patients with endometriosis: a randomized, double-blind, controlled trial 2025 · Curcumin and dienogest group · Women aged 18–45 with stage 2–3 pelvic endometriosis and moderate to severe pain | 80 mg | 8 weeks | 43 |
| Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial 2020 · nano-curcumin group · Patients with diabetes and diabetic polyneuropathy; age range and sex not reported | 80 mg | 8 weeks | 40 |
| The Effect of Nanocurcumin in Improvement of Knee Osteoarthritis: A Randomized Clinical Trial 2020 · nanocurcumin group · Patients with knee osteoarthritis; age and sex range not specified | 80 mg | 6 weeks | 36 |
| Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial 2018 · intervention group · Infertile men; age range and specific infertility diagnosis not stated | 80 mg | 10 weeks | 30 |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 960 mg | 16 weeks | 30 |
| Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo-controlled clinical trial 2024 · 80 mg nano-curcumin group · Patients with stage 3 or 4 severe COPD; age and sex not reported | 80 mg | 90 days | 30 |
| Comparison of oral Nano-Curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial 2020 · Group A (Curcumin) · Adults with erosive or atrophic oral lichen planus; age and sex ranges not specified | 80 mg | 4 weeks | 29 |
| Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial 2015 · curcumin capsules · Patients with active mild-to-moderate ulcerative colitis who did not respond to additional maximum-dose oral and topical mesalamine therapy | 3 g | 30 days | 26 |
| Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress 2017 · Curcumin group · Healthy men and postmenopausal women aged 45–74 years with age-related conduit artery endothelial dysfunction | 2 g | 12 weeks | 23 |
| Comparative evaluation of novel nano-herbal and photo-biomodulation therapy for gingivitis in visually impaired children: A randomized controlled study 2025 · Group C · Visually impaired children aged 8–14 years with mild to moderate gingivitis | 30 mg | 7 days | 20 |
| Curcumin supplementation likely attenuates delayed onset muscle soreness (DOMS) 2015 · curcumin · men completing unaccustomed heavy eccentric exercise; age and health status not reported | 5 g | 5 days | 17 |
| Efficacy of Curcumin in Combination with Intralesional Dexamethasone with Hyaluronidase in the Treatment of Oral Submucous Fibrosis: A Randomized Controlled Trial 2022 · Group A (Test) · Adults aged 18 years and older with clinically diagnosed oral submucous fibrosis (OSF) | 2 g | 6 weeks | 17 |
| Significant immunomodulatory properties of curcumin in patients with osteoarthritis; a successful clinical trial in Iran 2020 · intervention · Patients with osteoarthritis selected according to American College of Rheumatology criteria | 80 mg | 90 days | 15 |
| Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin 2015 · curcumin condition · Healthy, untrained men; mean age 23.5 years; no regular resistance training for at least 1 year | 50 mg | 1 day | 14 |
| The effect of curcumin and placebo on human gall-bladder function: an ultrasound study 1999 · curcumin · healthy volunteers, seven males and five females; age not reported | 20 mg | 1 day | 12 |
| Effect of different curcumin dosages on human gall bladder 2002 · 20 mg curcumin · 12 healthy volunteers; age and sex not specified | 20 mg | 1 day | 12 |
| Effect of different curcumin dosages on human gall bladder 2002 · 40 mg curcumin · 12 healthy volunteers; age and sex not specified | 40 mg | 1 day | 12 |
| Effect of different curcumin dosages on human gall bladder 2002 · 80 mg curcumin · 12 healthy volunteers; age and sex not specified | 80 mg | 1 day | 12 |
| Efficacy of curcumin for amelioration of radiotherapy-induced oral mucositis: a preliminary randomized controlled clinical trial 2023 · curcumin capsule · Adults over 18 with radiotherapy-induced oral mucositis (grades 1–3) receiving head-and-neck radiotherapy; men and women | 40 mg | 3 weeks | 12 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster) 2021 · higher-dose curcumin · Men aged 47–65 with Gulf War Illness | 4 g | 30 days | 10 |
| Effects of various food ingredients on gall bladder emptying 2013 · curcumin test product · healthy men and women aged 18–45 | 80 mg | 1 day | 8 |
| High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus 2012 · curcuminoids group · Adults with oral lichen planus; age and sex not reported | 6 g | 2 weeks | — |
| Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels 2018 · Acitretin plus nanocurcumin · Patients with moderate-to-severe psoriasis (PASI > 10); age and sex not reported | 3 g | 12 weeks | — |
| Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study 2019 · Curcumin · Patients with chronic schizophrenia; age and sex not reported | 3 g | 24 weeks | — |
| Eight Weeks of a High Dose of Curcumin Supplementation May Attenuate Performance Decrements Following Muscle-Damaging Exercise 2019 · high dose of curcumin (200 mg of curcuminoids = 1000 mg CurcuWIN®) · Men and women aged 19–29 years who were low to moderately trained and without stated musculoskeletal, medical, or metabolic contraindications to exercise | 3 g | 8 weeks | — |
| Effect of Nano-Curcumin on Radiotherapy-Induced Skin Reaction in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial 2022 · treatment group · Patients with breast cancer receiving radiotherapy | 80 mg | — | — |
| Adjunctive curcumin nano-micelles reduce overall pruritus intensity in refractory post-burn pruritus: A randomized controlled trial 2025 · Standard treatment plus curcumin nano-micelle capsules · Adults with refractory post-burn pruritus | 80 mg | 12 weeks | — |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO + CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 960 mg | 16 weeks | 30 |
| Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study 2018 · Curamin · Men and women aged 40–77 with degenerative hypertrophic knee osteoarthritis | 1.05 g | 12 weeks | 67 |
| Beneficial Effects on Abdominal Bloating with an Innovative Food-Grade Formulation of Curcuma longa and Boswellia serrata Extracts in Subjects with Irritable Bowel Syndrome and Small Bowel Dysbiosis 2022 · supplemented group · men and women aged 18–70 with irritable bowel syndrome, small bowel dysbiosis, and abdominal bloating | 1 g | 30 days | 33 |
| Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris 2015 · arm 1 · Adults with mild-to-moderate plaque psoriasis vulgaris (PASI < 10); sex and age range not specified | 200 mg | 12 weeks | 31 |
| The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial 2022 · curcumin-piperine group · Adults aged 18–65 with RT-PCR-confirmed COVID-19 who were outpatients and did not have severe disease requiring hospitalization | 1 g | 2 weeks | 23 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group II · Female patients with systemic lupus erythematosus (SLE); age not reported | 600 mg | 90 days | 15 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group III · Female patients with systemic lupus erythematosus (SLE); age not reported | 600 mg | 90 days | 15 |
| Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial 2025 · curcumin group · Adults over 50 years with hand osteoarthritis and hand pain or stiffness; mostly women | 86.3 mg | 90 days | 13 |
| Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study 2017 · combined low-dose curcumin extract plus saffron · People with major depressive disorder; age and sex not reported | 500 mg | 12 weeks | — |
| [Dry jelly concentrate with vitamins and dietary fiber in patients with IBS with constipation: a comparative controlled study] 2015 · Dry jelly concentrate group · Patients with IBS with constipation (IBS-C) meeting Rome III criteria; age and sex not reported | 20 mg | 2 weeks | — |
| Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial 2020 · combination of fish oil and curcumin · Sedentary overweight/obese adults aged 50–80 years | 160 mg | 16 weeks | — |
| Curcumin plus piperine improve body composition in patients with inflammatory bowel disease: a randomized, double-blind, placebo-controlled clinical trial 2025 · curcumin plus piperine · Adults aged 18 years or older with mild to moderate inflammatory bowel disease | 1 g | 12 weeks | — |
| Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial 2014 · curcumin extract capsule · Patients with metabolic syndrome; age range and sex not specified | 1.89 g | 12 weeks | 33 |
| Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis 2018 · Alendronate + curcumin · Postmenopausal women aged 55–65 with osteoporosis | 110 mg | 1 year | 20 |
| Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial 2025 · curcumin group · Adults aged 60 years and older with prediabetes and/or BMI ≥25 kg/m²; no preexisting diabetes | 80 mg | 12 weeks | 17 |
| Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study 2022 · Curcuminoids extract in powder · Healthy males and females aged 18–50 years | 200 mg | 1 day | 31 |
| The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes 2014 · Native powder · Healthy women and men; women and men aged not reported | 500 mg | 1 day | 23 |
| The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes 2014 · Micronized powder · Healthy women and men; women and men aged not reported | 500 mg | 1 day | 23 |
| The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes 2014 · Liquid micelles · Healthy women and men; women and men aged not reported | 500 mg | 1 day | 23 |
| Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open-label Parallel-arm Study 2017 · Volatile oil formulation · Healthy adult men | 500 mg | 1 day | 15 |
| Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open-label Parallel-arm Study 2017 · Phospholipid formulation · Healthy adult men | 500 mg | 1 day | 15 |
| A Comparative Pharmacokinetic Assessment of a Novel Highly Bioavailable Curcumin Formulation with 95% Curcumin: A Randomized, Double-Blind, Crossover Study 2018 · Unformulated 95% curcumin powder in capsule form · 12 healthy adult subjects | 323 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Native curcumin · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Liposome curcumin · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Submicron-particle curcumin · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Curcumin phytosomes · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Curcumin-γ-cyclodextrin complex · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Micellar curcumin · 12 healthy adults | 207 mg | 1 day | 12 |
| Oil-Based Curcuminoid Phospholipid Formulation Mimicking Natural Digestion Enhances Oral Bioavailability of Curcuminoids in Healthy Subjects 2024 · Oil/PL-based formulation · 12 healthy subjects; age range and sex not reported | 200 mg | 1 day | 12 |
| Oil-Based Curcuminoid Phospholipid Formulation Mimicking Natural Digestion Enhances Oral Bioavailability of Curcuminoids in Healthy Subjects 2024 · Pure curcuminoids extract (reference product) · 12 healthy subjects; age range and sex not reported | 200 mg | 1 day | 12 |
| Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse®) 2019 · Curcumin with LipiSperse® · Healthy male and female volunteers; ages not reported | 750 mg | 1 day | — |
| Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse®) 2019 · Raw curcumin product · Healthy male and female volunteers; ages not reported | 750 mg | 1 day | — |
| Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans 2019 · curcumin powder meal · healthy male participants; age not reported | 400 mg | 1 day | — |
| Comparative bioavailability of curcuminoids from a water-dispersible high curcuminoid turmeric extract against a generic turmeric extract: a randomized, cross-over, comparative, pharmacokinetic study 2021 · STE95 · 14 subjects; age, sex and health status not specified | 500 mg | 1 day | — |
| Supportive treatment of vascular dysfunction in pediatric subjects with obesity: the OBELIX study 2022 · Treatment group · Children aged 6–17 years with obesity (BMI above the 95th percentile for age) | 100 mg | 26 weeks | 16 |
| Supplementation with Whey Protein, Omega-3 Fatty Acids and Polyphenols Combined with Electrical Muscle Stimulation Increases Muscle Strength in Elderly Adults with Limited Mobility: A Randomized Controlled Trial 2020 · WPI + BIO · Adults aged 60–90 with mobility limitations and gait speed below 1.5 m/s | 500 mg | 12 weeks | 10 |
| Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial 2024 · Curcumin-treated group · Adults aged 35 years or older with obesity and recently diagnosed, well-controlled type 2 diabetes | 500 mg | 1 year | 114 |
| Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial 2013 · curcuminoids · Overweight or obese adults with type 2 diabetes | 300 mg | 90 days | 50 |
| Effects of Curcuminoids on Systemic Inflammation and Quality of Life in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial 2021 · curcuminoid group · Adults aged 20 years or older with stage-3 colorectal cancer who had surgery and were undergoing chemotherapy | 500 mg | 8 weeks | 36 |
| Effects of curcumin on cardiovascular risk factors in obese and overweight adolescent girls: a randomized clinical trial 2019 · curcumin group · Female adolescents aged 13–18 years with overweight or obesity | 500 mg | 10 weeks | 30 |
| The Effect of Dietary Supplementation With Curcumin on Redox Status and Nrf2 Activation in Patients With Nondiabetic or Diabetic Proteinuric Chronic Kidney Disease: A Pilot Study 2016 · CUR 320 mg/day, diabetic proteinuric CKD · Adults aged 20–70 with diabetic proteinuric chronic kidney disease | 320 mg | 8 weeks | 28 |
| The effect of Curcumin on metabolic parameters and androgen level in women with polycystic ovary syndrome: a randomized controlled trial 2023 · curcumin group · Women aged 18–45 with PCOS and BMI 18.5–40 | 500 mg | 12 weeks | 27 |
| The Effect of Dietary Supplementation With Curcumin on Redox Status and Nrf2 Activation in Patients With Nondiabetic or Diabetic Proteinuric Chronic Kidney Disease: A Pilot Study 2016 · CUR 320 mg/day, nondiabetic proteinuric CKD · Adults aged 20–70 with nondiabetic proteinuric chronic kidney disease | 320 mg | 8 weeks | 24 |
| A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study 2018 · CGM group · Men aged 30–50 with chronic alcohol use and elevated liver function markers, without diagnosed liver disease | 500 mg | 8 weeks | 24 |
| Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease 2021 · curcumin group · Patients with non-alcoholic fatty liver disease; age and sex not specified | 250 mg | 8 weeks | 22 |
| Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial 2022 · CP group (curcumin plus placebo) · Adults aged 18 years or older with metabolic syndrome; men and women | 200 mg | 12 weeks | 22 |
| Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial 2018 · curcumin (CC) · Hypercholesterolaemic individuals; age range and sex not reported | 200 mg | 4 weeks | 18 |
| Curcumin supplementation reduces blood glucose and serum lipids of Brazilian women with high waist circumference: a randomized clinical trial 2022 · Supplemented group (SG) · Adult and elderly Brazilian women aged 20 years or older with high waist circumference (≥80 cm) | 500 mg | 90 days | 15 |
| Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers 2007 · Curcumin with talinolol · 12 healthy Chinese volunteers | 300 mg | 7 days | 12 |
| Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study 2008 · NCB-02 · Patients with type 2 diabetes mellitus | 300 mg | 8 weeks | — |
| A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial 2019 · phospholipid curcumin group · Adults with non-alcoholic fatty liver disease (NAFLD); age range and sex not reported | 250 mg | 8 weeks | — |
| Effects of curcumin supplementation on markers of inflammation and oxidative stress among healthy overweight and obese girl adolescents: A randomized placebo-controlled clinical trial 2019 · intervention group · overweight and obese postpubescent adolescent girls | 500 mg | 10 weeks | — |
| The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial 2019 · curcumin group · Women with polycystic ovary syndrome who were overweight or obese; age range not reported | 500 mg | 6 weeks | — |
| Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial 2021 · curcumin group · Patients undergoing elective coronary angioplasty; age and sex not specified | 500 mg | 8 weeks | — |
| The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2021 · active intervention group · Adults with metabolic syndrome | 500 mg | 12 weeks | — |
| The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial 2021 · curcumin group · Patients with non-alcoholic fatty liver disease; age and sex not specified | 250 mg | 60 days | — |
| Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial 2022 · curcumin · Women with rheumatoid arthritis | 500 mg | 8 weeks | — |
| The efficacy of curcumin supplementation on serum total antioxidant capacity, malondialdehyde, and disease activity in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial 2024 · curcumin · women with rheumatoid arthritis | 500 mg | 8 weeks | — |
| Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial 2024 · curcumin · Patients with nonalcoholic simple fatty liver (NASFL); age and sex not reported | 500 mg | 24 weeks | — |
| Curcumin Reduces Depression in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial 2024 · curcumin-treated group (intervention) · Adults aged 35 years or older with obesity and type 2 diabetes diagnosed within the past 12 months; both sexes | 500 mg | 1 year | — |
| Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial 2024 · nanocurcumin + placebo · Women with polycystic ovary syndrome; age range not reported | 240 mg | 12 weeks | — |
| Effects of metformin and curcumin in women with polycystic ovary syndrome: A factorial clinical trial 2024 · metformin + nanocurcumin · Women with polycystic ovary syndrome; age range not reported | 240 mg | 12 weeks | — |
| Curcumin for Inflammation Control in Individuals with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial 2025 · curcumin group · Adults aged 35 years or older with type 2 diabetes mellitus and FibroScan-confirmed MASLD | 500 mg | 1 year | — |
| Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial 2025 · curcumin group · Adults aged 35 years or older with obesity and type 2 diabetes, using metformin for glycemic control | 500 mg | 1 year | — |
| Bread enriched with phytosterols with or without curcumin modulates lipoprotein profiles in hypercholesterolaemic individuals. A randomised controlled trial 2019 · PS-CC · People with hypercholesterolaemia; age and sex not reported | 228 mg | 4 weeks | — |
| Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study 2022 · Curcuminoids extract combined with rice oil · Healthy males and females aged 18–50 years | 200 mg | 1 day | 31 |
| The Effect of Curcumin on Serum Copper and Zinc and Zn/Cu Ratio in Individuals with Metabolic Syndrome: A Double-Blind Clinical Trial 2019 · curcumin · Individuals with metabolic syndrome | 1 g | 6 weeks | — |
| The Effect of Curcumin on Serum Copper and Zinc and Zn/Cu Ratio in Individuals with Metabolic Syndrome: A Double-Blind Clinical Trial 2019 · phospholipidated curcumin · Individuals with metabolic syndrome | 1 g | 6 weeks | — |
| Comparative bioavailability of curcuminoids from a water-dispersible high curcuminoid turmeric extract against a generic turmeric extract: a randomized, cross-over, comparative, pharmacokinetic study 2021 · WDTE60N · 14 subjects; age, sex and health status not specified | 150 mg | 1 day | — |
| Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial 2016 · curcumin · Patients with metabolic syndrome | 1 g | 8 weeks | 59 |
| Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial 2016 · curcumin · Males and females with metabolic syndrome; age range not reported | 1 g | 8 weeks | 59 |
| Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial 2016 · curcumin · Patients with nonalcoholic fatty liver disease, grades 1–3 | 1 g | 8 weeks | 50 |
| Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial 2017 · curcumin group · Patients diagnosed with NAFLD grades 1–3 | 1 g | 8 weeks | 50 |
| A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications 2012 · curcumin · Male Iranian veterans aged 37–59 with chronic sulphur mustard-induced pruritic skin lesions | 1 g | 4 weeks | 46 |
| The Combined Effects of an Anti-Inflammatory Diet and Curcumin Supplementation on Thyroid Function and Lipid Profile in Patients With Hashimoto's Thyroiditis: A Double Blind Randomised Clinical Trial 2026 · curcumin group · Adults aged 20–70 with Hashimoto's thyroiditis; 89.3% female in the analysed group | 1.32 g | 12 weeks | 31 |
| Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial 2013 · curcuminoids · Obese individuals with dyslipidemia; age range and sex not specified | 1 g | 30 days | 30 |
| Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals 2013 · curcuminoids · 30 obese individuals | 1 g | 30 days | 30 |
| Nanomicelle curcumin improves oxidative stress, inflammatory markers, and assisted reproductive techniques outcomes in endometriosis cases: a randomized clinical trial 2025 · intervention group · Women aged 25–35 with stage III/IV endometriosis who were candidates for assisted reproductive techniques | 120 mg | 10 weeks | 25 |
| Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial 2022 · nanocurcumin group · COVID-19 patients; age range and sex not stated | 160 mg | 6 days | 24 |
| Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD 2016 · Theracurmin group · Men and women aged 20–85 with stage I or II COPD | 180 mg | 26 weeks | 22 |
| Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients 2020 · Nano-curcumin group · Adults aged 19–69 with confirmed COVID-19 in the ARDS phase | 160 mg | 2 weeks | 20 |
| Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism 2012 · Curcumin-treated phase · Healthy male volunteers with different ABCB1 C3435T genotypes | 1 g | 2 weeks | 18 |
| Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial 2022 · Micellar curcumin · Healthy volunteers aged 18–60 years, men and women | 129 mg | 7 days | 16 |
| Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial 2022 · Native curcumin · Healthy volunteers aged 18–60 years, men and women | 129 mg | 7 days | 16 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · CC (curcumin) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 180 mg | 12 weeks | 15 |
| Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus 2019 · Theracurmin® · Men and women aged 20–85 with impaired glucose tolerance or non-insulin-dependent diabetes mellitus | 180 mg | 26 weeks | 15 |
| Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial 2023 · CURC · Healthy adults aged 18–65 who had recovered from asymptomatic, mild, or moderate COVID-19 and subsequently received a primary series of COVID-19 vaccine doses | 1 g | 4 weeks | 15 |
| Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3β and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer's Disease 2020 · curcumin group · Adults aged 30–70 with overweight or obesity and impaired fasting glucose and/or impaired glucose tolerance, at high risk of type 2 diabetes | 180 mg | 12 weeks | 14 |
| Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study 2012 · exercise training with curcumin ingestion · postmenopausal women | 150 mg | 8 weeks | 12 |
| Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study 2012 · curcumin ingestion · postmenopausal women | 150 mg | 8 weeks | 11 |
| Effects of curcumin supplementation on exercise-induced oxidative stress in humans 2014 · double (before and immediately after exercise) · Men, mean age 26.8 years, completing treadmill exercise | 180 mg | 1 day | 10 |
| Benefits of Curcumin Supplementation on Antioxidant Status in β-Thalassemia Major Patients: A Double-Blind Randomized Controlled Clinical Trial 2017 · curcumin group · Patients with β-thalassemia major | 1 g | 12 weeks | — |
| The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease 2019 · curcumin · Patients with non-alcoholic fatty liver disease | 1.5 g | 12 weeks | — |
| The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial 2019 · curcumin group · patients with type 2 diabetes | 1.5 g | 10 weeks | — |
| Effect of Curcumin Supplementation on Exercise-Induced Oxidative Stress, Inflammation, Muscle Damage, and Muscle Soreness 2020 · curcumin group · males; age and health condition not specified | 1.5 g | 4 weeks | — |
| Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity 2020 · curcumin · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²) | 160 mg | 16 weeks | — |
| Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial 2021 · curcumin group · Individuals with polycystic ovary syndrome (age and sex not specified) | 1.5 g | 12 weeks | — |
| Antioxidant and anti-inflammatory response to curcumin supplementation in hemodialysis patients: A randomized, double-blind, placebo-controlled clinical trial 2021 · curcumin group · Hemodialysis patients; age range and sex not specified | 1 g | 12 weeks | — |
| Co-Administration of Iron and Bioavailable Curcumin Reduces Levels of Systemic Markers of Inflammation and Oxidative Stress in a Placebo-Controlled Randomised Study 2022 · FS18_Curc (ferrous sulphate—18 mg elemental iron + 500 mg curcumin) · Generally healthy adults aged 18–40 years with ferritin in the normal range; men and women | 500 mg | 6 weeks | — |
| Curcumin and vitamin E improve hot flashes, lipid profile, and fasting blood glucose without any detrimental effect on the liver and renal function in postmenopausal women: A triple-blind placebo-controlled clinical trial 2024 · Curcumin group · Postmenopausal women | 1 g | 8 weeks | — |
| Therapeutic Potential of Curcumin with and without Strengthening Exercises in Improving Rheumatoid Arthritis 2022 · Group A · Patients with rheumatoid arthritis; age and sex not reported | 180 mg | 24 weeks | — |
| Therapeutic Potential of Curcumin with and without Strengthening Exercises in Improving Rheumatoid Arthritis 2022 · Group B · Patients with rheumatoid arthritis; age and sex not reported | 180 mg | 24 weeks | — |
| The effects of curcumin supplementation on inflammatory markers in systemic lupus erythematosus patients: a randomized placebo-controlled trial 2024 · Curcumin group · Adults aged 18–60 with systemic lupus erythematosus (SLE) | 1 g | 10 weeks | — |
| Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects 2021 · CR-033P · Healthy men aged 19–60 years | 90 mg | 1 day | 24 |
| Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects 2021 · CR-031P · Healthy men aged 19–60 years | 30 mg | 1 day | 24 |
| Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects 2021 · Unformulated curcumin powder · Healthy men aged 19–60 years | 90 mg | 1 day | 24 |
| Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers 2017 · standard curcumin extract · Healthy male and female volunteers aged 18–65 years | 2.92 g | 7 days | 16 |
| A Comparative Pharmacokinetic Assessment of a Novel Highly Bioavailable Curcumin Formulation with 95% Curcumin: A Randomized, Double-Blind, Crossover Study 2018 · CLDM (curcumin liquid droplet micromicellar formulation) · 12 healthy adult subjects | 64.6 mg | 1 day | 12 |
| Urine and serum analysis of consumed curcuminoids using an IkappaB-luciferase surrogate marker assay 2010 · curcuminoid test group · Men and women aged 18 years or older with normal organ function | 8 g | 1 day | 10 |
| Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects 2008 · 10 g dose · Healthy adults aged 18–65 years, all Caucasian, with normal organ function | 10 g | 1 day | 6 |
| Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects 2008 · 12 g dose · Healthy adults aged 18–65 years, all Caucasian, with normal organ function | 12 g | 1 day | 6 |
| Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial 2021 · Group 2 · Women with polycystic ovary syndrome diagnosed according to the Rotterdam criteria | 80 mg | 90 days | 50 |
| The effects of curcumin supplementation on oxidative stress, Sirtuin-1 and peroxisome proliferator activated receptor γ coactivator 1α gene expression in polycystic ovarian syndrome (PCOS) patients: A randomized placebo-controlled clinical trial 2020 · curcumin · Patients with polycystic ovarian syndrome (PCOS); age and sex details not stated | 4.5 g | 90 days | 36 |
| Acute Administration of Bioavailable Curcumin Alongside Ferrous Sulphate Supplements Does Not Impair Iron Absorption in Healthy Adults in a Randomised Trial 2021 · FS18_Curc (ferrous sulphate–18 mg elemental iron + 500 mg curcumin) · Healthy adults aged 18–40 years with ferritin in the normal UK range | 500 mg | 1 day | 31 |
| Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial 2014 · Curcuminoids · Adults aged 18–65 with obesity (BMI ≥30) and specified coronary heart disease risk factors and LDL-C levels | 1 g | 30 days | 30 |
| The Effects of Nano-curcumin on Metabolic Status in Patients With Diabetes on Hemodialysis, a Randomized, Double Blind, Placebo-controlled Trial 2020 · nano-curcumin group · Patients with diabetes on hemodialysis | 80 mg | 12 weeks | 30 |
| The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial 2021 · nanocurcumin group · patients with grade 3 diabetic foot ulcer; age and sex not reported | 80 mg | 12 weeks | 30 |
| Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial 2025 · nano-curcumin group · Adults aged 30–70 with NAFLD-associated liver fibrosis, stage F2 or higher; men and women | 80 mg | 16 weeks | 27 |
| The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker 2009 · Curcumin · Patients with monoclonal gammopathy of undetermined significance (MGUS) | 4 g | — | 26 |
| Impaired postprandial GLP-2 response enhances endotoxemia, systemic inflammation, and kidney injury in metabolic dysfunction-associated steatohepatitis (MASH): effect of phospholipid curcumin meriva 2024 · Meriva (phospholipid curcumin) · Adults with biopsy-proven MASH, with or without chronic kidney disease; ages approximately 53–56 years | 2 g | 72 weeks | 26 |
| The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: A randomized, double-blind clinical trial 2021 · nano-curcumin group · Patients with metabolic syndrome; age and sex not specified | 80 mg | 12 weeks | 25 |
| The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study 2022 · nano-curcumin group · Adults aged 20–50 with BMI 25–35 and episodic migraine; 42 women and 2 men enrolled overall | 80 mg | 60 days | 22 |
| Effects of curcumin and/or coenzyme Q10 supplementation on metabolic control in subjects with metabolic syndrome: a randomized clinical trial 2022 · CQ group (curcumin plus coenzyme Q10) · Adults aged 18 years or older with metabolic syndrome; men and women | 200 mg | 12 weeks | 22 |
| Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial 2024 · nano-curcumin · Overweight or obese adults aged 35–70 with coronary slow flow phenomenon | 80 mg | 12 weeks | 21 |
| Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study 2016 · curcumin group (CG) · Patients with prostate cancer undergoing radiotherapy; age and sex not stated | 3 g | — | 20 |
| Analysis of Curcumin as a Radiosensitizer in Cancer Therapy with Serum Survivin Examination: Randomised Control Trial 2021 · Curcumin + radiation · Women with stage IIB–IIIB cervical carcinoma receiving radiotherapy | 4 g | 7 days | 20 |
| Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial 2025 · Curcumin group · Adults aged 35–70 with uncontrolled type 2 diabetes treated with glimepiride | 1.1 g | 12 weeks | 20 |
| Nanocurcumin supplementation ameliorates Behcet's disease by modulating regulatory T cells: A randomized, double-blind, placebo-controlled trial 2021 · nanocurcumin group · Adults with Behçet's disease | 80 mg | 8 weeks | 17 |
| Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study 2018 · curcumin (CC) · Healthy men and women aged 18–45 years with BMI below 30 kg/m² | 90 mg | 1 day | 15 |
| Effects of curcumin supplementation on exercise-induced oxidative stress in humans 2014 · single (only before exercise) · Men, mean age 26.8 years, completing treadmill exercise | 90 mg | 1 day | 10 |
| Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial 2016 · curcumin group · Patients with ultrasonographic evidence of non-alcoholic fatty liver disease | 70 mg | 8 weeks | — |
| An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β-thalassemia major patients: A double-blind randomized controlled clinical trial 2018 · Curcumin group · Patients with β-thalassemia major; age and sex not specified | 2 g | 12 weeks | — |
| A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study 2018 · Nanocurcumin group · Patients with episodic migraine | 80 mg | 60 days | — |
| Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial 2021 · nano-curcumin group · Patients undergoing elective coronary angioplasty; age and sex not specified | 80 mg | 8 weeks | — |
| Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial 2023 · nano-curcumin · Patients with type 2 diabetes and mild to moderate coronary artery disease; age and sex not stated | 80 mg | 90 days | — |
| "The protective effect of nano curcumin supplementation on doxorubicin induced cardiotoxicity in breast cancer patients; a randomized, double-blind clinical trial" 2025 · curcumin group · Breast cancer patients receiving doxorubicin chemotherapy; age and sex details not reported | 80 mg | 26 weeks | — |
| Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial 2016 · curcuminoids + piperine combination · Adults with chronic pulmonary complications due to sulfur mustard exposure | 1.5 g | 4 weeks | 45 |
| Effects of curcumin supplementation on vitamin D levels in women with premenstrual syndrome and dysmenorrhea: a randomized controlled study 2022 · CUR group · Single women aged 18–24 with moderate to severe premenstrual syndrome and dysmenorrhea | 500 mg | 90 days | 38 |
| Comparative Pharmacokinetic of Curcuminoids Formulations with an Omega-3 Fatty Acids Monoglyceride Carrier: A Randomized Cross-Over Triple-Blind Study 2022 · Curcuminoids extract emulsified in MAG-OM3 oil · Healthy males and females aged 18–50 years | 200 mg | 1 day | 31 |
| Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers 2017 · curcumin phosphatidylcholine extract · Healthy male and female volunteers aged 18–65 years | 385 mg | 7 days | 16 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Curcumin with turmeric oils · 12 healthy adults | 207 mg | 1 day | 12 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Curcumin with adjuvants, including piperine · 12 healthy adults | 207 mg | 1 day | 12 |
| Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans 2019 · turmeric powder meal · healthy male participants; age not reported | 400 mg | 1 day | — |
| Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans 2019 · grated fresh turmeric root meal · healthy male participants; age not reported | 400 mg | 1 day | — |
| Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis 2015 · curcuminoids · Adults with metabolic syndrome diagnosed according to NCEP-ATPIII criteria | 1 g | 8 weeks | 59 |
| Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial 2014 · curcuminoids · Patients diagnosed with metabolic syndrome according to NCEP-ATPIII criteria and receiving standard of care | 1 g | 8 weeks | 50 |
| Curcuminoids Plus Piperine Modulate Adipokines in Type 2 Diabetes Mellitus 2017 · curcuminoids versus placebo group · Patients with type 2 diabetes; age and sex not reported | 1 g | 12 weeks | 50 |
| Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial 2018 · curcuminoids · Adults aged 18–65 with type 2 diabetes mellitus | 500 mg | 90 days | 50 |
| Effects of curcumin-piperine supplementation on systemic immunity in young women with premenstrual syndrome and dysmenorrhea: A randomized clinical trial 2022 · curcumin · Young women with premenstrual syndrome and primary dysmenorrhea | 500 mg | — | 40 |
| The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial 2021 · active intervention group · Patients aged 18–75 years with acute myocardial infarction | 500 mg | 8 weeks | 38 |
| Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhea: A randomized controlled trial 2023 · Curcumin (CUR) group · Women aged 18–24 with moderate-to-severe premenstrual syndrome and dysmenorrhea | 500 mg | — | 38 |
| The effects of curcumin-piperine supplementation on inflammatory, oxidative stress and metabolic indices in patients with ischemic stroke in the rehabilitation phase: a randomized controlled trial 2023 · curcumin-piperine group · Adults aged 20–65 years with ischemic stroke in the rehabilitation phase, 3–6 months after the active stroke attack | 500 mg | 12 weeks | 33 |
| Therapeutic effects of curcumin and piperine combination in critically ill patients with sepsis: a randomized double-blind controlled trial 2025 · intervention group (curcumin-piperine) · Adults aged 20–75 with sepsis admitted to an ICU | 1 g | 7 days | 33 |
| Acute Administration of Bioavailable Curcumin Alongside Ferrous Sulphate Supplements Does Not Impair Iron Absorption in Healthy Adults in a Randomised Trial 2021 · FS65_Curc (ferrous sulphate–65 mg elemental iron + 500 mg curcumin) · Healthy adults aged 18–40 years with ferritin in the normal UK range | 500 mg | 1 day | 31 |
| Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial 2023 · curcumin + piperine · Patients with moderate-to-high non-alcoholic fatty liver disease diagnosed by liver sonography; age and sex not specified | 500 mg | 12 weeks | 30 |
| Curcumin and Boswellia serrata Modulate the Glyco-Oxidative Status and Lipo-Oxidation in Master Athletes 2016 · Group 2 (curcumin/BSE group; MD plus Fitomuscle®) · Healthy male master cyclists, mean age 46 ± 8 years, without the listed cardiovascular, metabolic or chronic inflammatory conditions | 10 mg | 12 weeks | 25 |
| Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study 2011 · trial group · Patients with overt type 2 diabetic nephropathy; age and sex not specified | 66.3 mg | 60 days | 20 |
| Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial 2016 · curcuminoids group · Adults with mild-to-moderate primary knee osteoarthritis | 1.5 g | 6 weeks | 19 |
| Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial 2018 · combination of phytosterols and curcumin (PS-CC) · Hypercholesterolaemic individuals; age range and sex not reported | 200 mg | 4 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 180 mg | 12 weeks | 16 |
| Bioactive Yoghurt Containing Curcumin and Chlorogenic Acid Reduces Inflammation in Postmenopausal Women 2022 · bioactive yoghurt · Women aged 45–65, overweight or obese (BMI 25–40), postmenopausal for at least one year | 103 mg | 1 day | 16 |
| Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study 2012 · trial group · Patients with relapsing or refractory biopsy-proven lupus nephritis | 66.3 mg | 90 days | 12 |
| Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial 2017 · curcuminoids · People with type 2 diabetes | 1 g | 12 weeks | — |
| A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study 2018 · Combination of ω-3 fatty acids plus nano-curcumin · Patients with episodic migraine | 80 mg | 60 days | — |
| Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial 2019 · curcumin intervention group · Men aged 18–35 years with obesity (BMI ≥30.0 kg/m²) | 500 mg | 12 weeks | — |
| Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial 2019 · curcuminoids plus piperine · Adults with ultrasound-determined nonalcoholic fatty liver disease; age and sex not specified | 500 mg | 12 weeks | — |
| Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial 2020 · curcuminoids group · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 500 mg | 8 weeks | — |
| Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomized double-blind placebo-controlled trial 2020 · Curcuminoids · Critically ill patients aged 18–65 years with traumatic brain injury | 500 mg | 7 days | — |
| Ubiquitin Proteasome System Activity is Suppressed by Curcumin following Exercise-Induced Muscle Damage in Human Skeletal Muscle 2021 · curcumin (CUR) group · Recreationally active males and females aged 18–30 | 2 g | 11 days | — |
| Co-Administration of Iron and Bioavailable Curcumin Reduces Levels of Systemic Markers of Inflammation and Oxidative Stress in a Placebo-Controlled Randomised Study 2022 · FS65_Curc (ferrous sulphate—65 mg elemental iron + 500 mg curcumin) · Generally healthy adults aged 18–40 years with ferritin in the normal range; men and women | 500 mg | 6 weeks | — |
| Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial 2023 · curcumin-piperine · Patients with COVID-19 admitted to the intensive care unit; age and sex not specified | 1.5 g | 7 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group B · Adults who underwent coronary artery bypass graft surgery | 500 mg | 5 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group C · Adults who underwent coronary artery bypass graft surgery | 1 g | 5 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group D · Adults who underwent coronary artery bypass graft surgery | 1.5 g | 5 days | — |
| A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease 2022 · Nutraceutical (Livogen Plus®) · Adults aged 30–75 with hepatic steatosis (NAFLD), without diabetes | 667 mg | 12 weeks | 70 |
| Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial 2020 · Phytosomal curcumin · Adults aged 18–70 years with overweight (BMI 25–30 kg/m²) and suboptimal fasting plasma glucose (100–125 mg/dL) | 200 mg | 8 weeks | 40 |
| Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial 2021 · curcumin group · Adults aged 18–65 with non-alcoholic fatty liver disease diagnosed by liver sonography | 500 mg | 60 days | 39 |
| Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity 2020 · combination · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²) | 160 mg | 16 weeks | — |